In gliomas, miR-383 targets insulin-like growth factor 1 receptor (IGF1R), leading to suppression of AKT signaling and downregulation of matrix metalloproteinase 2 (MMP2), thereby inhibiting glioma cell invasion. This evidence concerns the gene AKT1 and central nervous system cancer.